New study shows district hospitals can offer specialized prenatal diagnostics for thalassemia and sickle cell disease,opening new doors for rural and semi-urban families in India. Sankalp India Foundation,working with state governments and health orgs,published the findings in Blood Global Hematology.
Since 2021,over 218,000 pregnant women in 82 districts joined a screening program targeting hemoglobin disorders. This initiative created a referral network allowing 2,092 invasive prenatal procedures,preventing 286 births with severe conditions. No need for city travel now; program links at-risk women with nearby specialists.
“Invasive prenatal diagnosis used to be city-only — Delhi,Mumbai,Hyderabad,Bengaluru,” said Rajat Kumar Agarwal, President of Sankalp India Foundation. For many in tribal areas,traveling during pregnancy wasn't feasible. The program bridged this gap by connecting screening centers with 26 fetal medicine facilities and labs.
Focuses on thalassemia and sickle cell disease,using same tests. Agarwal said this combined approach was key from start. District hospitals are entry points for advanced preventive healthcare,with most families using local public health facilities.
Researchers saw no sample loss,little diagnostic failure,despite logistical challenges. Digital platform StopThal coordinated counseling,referrals,labs,and tracking . Of high-risk couples,66.2% chose invasive testing after counseling,61.7% completed diagnosis. Nearly two-thirds of families with affected fetuses opted for termination after informed talks.
Safety outcomes promising,spontaneous abortion rate just 0.4%,matching international standards. Agarwal noted takeaway: advanced diagnostics delivered without new infrastructure. “Policy talks often assume new infrastructure is needed for advanced services. This study shows existing systems can be strengthened to achieve same outcomes,” he said.
Study supports three-step model: screening firmation,then invasive diagnosis . Offers scalable way to reduce impact of transfusion-dependent thalassemia and severe sickle cell disease in India.
Agarwal said findings matter as national screening grows, but access to prenatal diagnosis still uneven. “Challenge isn’t proving prevention works. It’s ensuring every at-risk family,wherever they live,has informed choices and timely diagnosis,” he concluded.
